Mario Correale

Mario Correale

Auto-generated profile, based on publicly available information

Mario Correale

National Institute of Gastroenterology, “Saverio de Bellis” Research Hospital

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
PIPalma Iacovazzi
Palma Iacovazzi
RCRaffaele Cozzolongo
Raffaele Cozzolongo
ELElsa Lanzillotta
Elsa Lanzillotta
SFStefania Frisullo
Stefania Frisullo
VGVito Guerra
Vito Guerra
MCMario Correale
Mario Correale
90K/Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Quite interestingly, 90K/Mac-2BP is associated to a poor response to interferon (IFN) alpha in hepatitis C virus (HCV) infected patients. Here, in 70 consecutive HCV chronic patients, we have evaluated 90K basal levels as a response predictor to combined therapy with Peginterferon and Ribavirin. We have found higher 90K levels in genotype 1/4 than in genotype 2/3 (p = 0.006) and in 62.5% of non-responders than in 20% of responders (p < 0.001). Genotype 1/4, higher 90K and gamma glutamyl transferase (gammaGT) levels resulted independently associated to a status of refractoriness to therapy. Consequently, evaluation of 90K serum levels seems to be a promising useful marker of response to combined therapy in HCV disease.

27 February 2019 in Revista de la Facultad de Ciencias Médicas de Córdoba
Verified
Journal Article
Open access
PDF file
IFIsabella Franco
Isabella Franco
ABAntonella Bianco
Antonella Bianco
MDMaría Pilar del Díaz
María Pilar del Díaz
CBcaterina Bonfiglio
caterina Bonfiglio
MCMarisa Chiloiro
Marisa Chiloiro
AOAlberto Rubén Osella
Alberto Rubén Osella
Introduction: To estimate the effectiveness of two physical activity programs on NAFLD.Methods: Participants come from a survey conducted in southern Italy. Subjects with moderate or severe NAFLD were invited to participate. After giving informed consent, they completed a questionnaire, underwent ultrasonography and anthropometric measurements. Then they were randomized an Aerobic or a Combined Exercise program and followed up for six months. The first group followed a program of moderate aerobic activity lasting 30 minutes, 5 days per week. The second group did aerobic training with the addition of muscle training involving the large muscle groups, stimulating them to make more intense efforts, for a duration of 60 minutes, at least, 3 days a week. Compliance with the programs was measured. A mixed linear model was applied to the data.Results: Compliance with Aerobic Exercise was homogeneous and increased over time. Combined Program compliance was equal to 100%. There was no significant difference in the NAFLD mean score by treatment at baseline and after six months. However, there was a significant reduction in the NAFLD mean score for treatments after six months. The NAFLD measured score was reduced by 22% in the Aerobic treatment group when confronted with the other program. In the Combined program, after 6 months, results showed to be less effective than the Aerobic Exercise in reducing the NAFLD score.Conclusions: An aerobic exercise program is a realistic intervention which could be included as a part of primary prevention of several chronic diseases.